Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: INVA
- CUSIP: 88338T10
- Previous Close: $12.01
- 50 Day Moving Average: $11.07
- 200 Day Moving Average: $11.01
- 52-Week Range: $107,639,000.00 - $8.67
- Trailing P/E Ratio: 22.72
- Foreward P/E Ratio: 8.42
- P/E Growth: 0.13
- Market Cap: $1.30B
- Outstanding Shares: 107,639,000
- Beta: 2.33
- Net Margins: 44.57%
- Return on Equity: -20.31%
- Return on Assets: 19.38%
Companies Related to Innoviva:
- Debt-to-Equity Ratio: -2.03%
- Current Ratio: 17.36%
- Quick Ratio: 12.47%
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
Where is Innoviva's stock going? Where will Innoviva's stock price be in 2017?
2 brokerages have issued 1-year target prices for Innoviva's stock. Their predictions range from $11.00 to $15.00. On average, they expect Innoviva's stock price to reach $13.00 in the next twelve months.
When will Innoviva announce their earnings?
Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
Who owns Innoviva stock?
Innoviva's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (13.60%), Iridian Asset Management LLC CT (7.01%), Sarissa Capital Management LP (2.74%), State Street Corp (1.94%), GLG LLC (0.75%) and Guggenheim Capital LLC (0.25%). Company insiders that own Innoviva stock include Eric Desparbes, James L Tyree, Plc Glaxosmithkline and Theodore L Witek Jr.
Who sold Innoviva stock? Who is selling Innoviva stock?
Innoviva's stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, FMR LLC, Tudor Investment Corp Et Al, Pacad Investment Ltd., Federated Investors Inc. PA, Allianz Asset Management AG, Old West Investment Management LLC and TCW Group Inc.. Company insiders that have sold Innoviva stock in the last year include Eric Desparbes, James L Tyree and Theodore L Witek Jr.
Who bought Innoviva stock? Who is buying Innoviva stock?
Innoviva's stock was acquired by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, GLG LLC, State Street Corp, Guggenheim Capital LLC, Comerica Bank, Public Sector Pension Investment Board, Dimensional Fund Advisors LP and Thrivent Financial for Lutherans.
How do I buy Innoviva stock?
Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Innoviva stock cost?
One share of Innoviva stock can currently be purchased for approximately $12.04.